Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 10:22 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1729–1752 of 4,241 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Study Product Clear all
Completed Phase 4 Interventional Results available

The Effects of IV vs Oral Dexamethasone on Postoperative Nausea, Vomiting, and Pain

NCT04563494
View directory record Official record
Conditions
Nausea and Vomiting, Postoperative
Interventions
dexamethasone
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
3 Years to 7 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Nov 2, 2026, 10:22 AM EST
Completed Phase 4 Interventional Results available

Low Dose Ketamine for Blunt Thoracic Trauma

NCT06236113
View directory record Official record
Conditions
Blunt Injury of Thorax, Multiple Rib Fractures, Involving Three Ribs
Interventions
Ketamine 1 Mg/mL-NaCl 0.9% Intravenous Solution
Drug
Lead sponsor
North Memorial Health Care
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Robbinsdale, Minnesota
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Nov 2, 2026, 10:22 AM EST
Terminated Phase 3 Interventional

Efficacy of Ramelteon in Adults With Chronic Insomnia

NCT00672724
View directory record Official record
Conditions
Chronic Insomnia
Interventions
Ramelteon, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 64 Years
Enrollment
1,081 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
43
States / cities
Mesa, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2012 · Synced Nov 2, 2026, 10:22 AM EST
Completed Phase 3 Interventional

Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma

NCT04987203
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Tivozanib, Nivolumab
Drug
Lead sponsor
AVEO Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 130 Years
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
36
States / cities
Duarte, California • Irvine, California • La Jolla, California + 31 more
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Nov 2, 2026, 10:22 AM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Clinical Study Investigating the Efficacy of a Stannous Fluoride Dentifrice in Improving Gingival Health After Twice Daily Use for 3 Weeks

NCT04050722
View directory record Official record
Conditions
Gingivitis
Interventions
Sensodyne Repair and Protect, Colgate Cavity Protection
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Nov 19, 2020 · Synced Nov 2, 2026, 10:22 AM EST
Active, not recruiting Phase 2 Interventional

RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)

NCT04567550
View directory record Official record
Conditions
Diabetic Retinopathy (DR), Center-Involved Diabetic Macular Edema (CI-DME)
Interventions
ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, ABBV-RGX-314 Dose 3, Topical Steroid, ABBV-RGX-314 Dose 4, Aflibercept
Genetic · Drug · Biological
Lead sponsor
AbbVie
Industry
Eligibility
25 Years to 89 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
25
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Nov 2, 2026, 10:22 AM EST
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study Comparing Estradiol Vaginal Inserts 4mcg To IMVEXXY ® (Estradiol Vaginal Inerts 4 mcg) In The Treatment Of Dyspareunia in Women With Vulvur and Vaginal Atrophy

NCT05617820
View directory record Official record
Conditions
Dyspareunia
Interventions
Estradiol, Imvexxy, Placebo
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
1,050 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
42
States / cities
Birmingham, Alabama • Chandler, Arizona • Sacramento, California + 36 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Nov 2, 2026, 10:22 AM EST
Withdrawn Phase 2 Interventional

Treatment of Lung Injury From COVID-19 Infection With Intravenous Sodium Nitrite

NCT04401527
View directory record Official record
Conditions
COVID-19, Acute Respiratory Distress Syndrome, Acute Respiratory Failure
Interventions
Sodium Nitrite, Normal Saline
Drug
Lead sponsor
Hope Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
2
States / cities
Tampa, Florida • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Nov 2, 2026, 10:22 AM EST
Completed Phase 1 Interventional

ERX1000 - Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Male and Female Subjects With Obesity

NCT04890873
View directory record Official record
Conditions
Obesity
Interventions
ERX1000, Placebo
Drug
Lead sponsor
ERX Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 24, 2023 · Synced Nov 2, 2026, 10:22 AM EST
Completed Phase 2 Interventional Results available

Furoscix in Heart Failure Patients With Diuretic Resistance

NCT05528588
View directory record Official record
Conditions
Heart Failure
Interventions
Furoscix, Diuretic Therapy
Combination Product · Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Nov 2, 2026, 10:22 AM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Weekly Dosing of Malarone ® for Prevention of Malaria

NCT00984256
View directory record Official record
Conditions
Malaria
Interventions
Atovaquone Proguanil, Procedure - malaria challenge
Drug · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 50 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 25, 2013 · Synced Nov 2, 2026, 10:22 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

A Controlled Study to Evaluate the Effects of a Supplement on Weight Loss, Blood Sugar, and Appetite Suppression

NCT07889570
View directory record Official record
Conditions
Overweight, Obesity, Blood Sugar Regulation, Appetite Suppression, Weight Management
Interventions
Evolv GLP-1 Group, Control Group
Dietary Supplement · Other
Lead sponsor
Evolv
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Nov 2, 2026, 10:22 AM EST
Completed Phase 2 Interventional Results available

Study to Assess Enobosarm (GTx-024) in Postmenopausal Women With Stress Urinary Incontinence

NCT03241342
View directory record Official record
Conditions
Stress Urinary Incontinence
Interventions
GTx 024, Placebo
Drug
Lead sponsor
GTx
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
491 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
62
States / cities
Homewood, Alabama • Mobile, Alabama • Anchorage, Alaska + 57 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2021 · Synced Nov 2, 2026, 10:22 AM EST
Completed Phase 3 Interventional Results available

Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert

NCT01694186
View directory record Official record
Conditions
Non-Infectious Uveitis
Interventions
FAI insert, Sham injection
Drug
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
16
States / cities
Beverly Hills, California • Sacramento, California • Torrance, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2021 · Synced Nov 2, 2026, 10:22 AM EST
Completed Early Phase 1 Interventional Accepts healthy volunteers

ICG to Assess Ovarian Perfusion

NCT03927651
View directory record Official record
Conditions
Fibroid Uterus, Endometriosis, Uterus Myoma, Uterine Fibroid, Uterine Adenomyosis, Endometrial Cyst, Uterine Cyst
Interventions
ICG
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Nov 2, 2026, 10:22 AM EST
Completed Phase 4 Interventional Results available

Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to <2 Years (MK-8616-169)

NCT03909165
View directory record Official record
Conditions
Neuromuscular Blockade
Interventions
Sugammadex 2 mg/kg, Sugammadex 4 mg/kg, Neostigmine + Glycopyrrolate, Neostigmine + Atropine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
1 Day to 2 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
7
States / cities
Palo Alto, California • Miami, Florida • Oklahoma City, Oklahoma + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2025 · Synced Nov 2, 2026, 10:22 AM EST
Recruiting Phase 2Phase 3 Interventional

A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025).

NCT07722611
View directory record Official record
Conditions
Polycythemia Vera
Interventions
Bomedemstat, Ruxolitinib, Ropeginterferon alfa-2b
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Nov 2, 2026, 10:22 AM EST
Active, not recruiting Phase 2 Interventional

Safety and Efficacy Study of Sivopixant, Acetazolamide and SASS-001 in Sleep Apnea

NCT06776432
View directory record Official record
Conditions
Sleep Apnea
Interventions
Sivopixant, Placebo, Acetazolamide, SASS-001
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
9
States / cities
La Jolla, California • Brandon, Florida • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Nov 2, 2026, 10:22 AM EST
Completed Phase 1Phase 2 Interventional Results available

A Pilot Study of the Effects on Sleep Disordered Breathing (SDB) When Using the Drug Liraglutide for 4 Weeks

NCT01832532
View directory record Official record
Conditions
Sleep Apnea, Sleep Disordered Breathing
Interventions
liraglutide
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years to 60 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 20, 2020 · Synced Nov 2, 2026, 10:22 AM EST
Terminated Phase 2 Interventional Results available

A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung

NCT00752206
View directory record Official record
Conditions
Osteosarcoma
Interventions
Saracatinib, Placebo
Drug
Lead sponsor
Sarcoma Alliance for Research through Collaboration
Other
Eligibility
15 Years to 74 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Nov 2, 2026, 10:22 AM EST
Completed Phase 2 Interventional Results available

Baked Milk Oral Immunotherapy for Cow's Milk Allergy

NCT03462030
View directory record Official record
Conditions
Cow's Milk Allergy
Interventions
Baked non-fat cow's milk powder, Placebo: Tapioca Powder
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
3 Years to 18 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Nov 2, 2026, 10:22 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Safety, Tolerability and Pharmacokinetics of NRX-1074 in Normal Healthy Volunteers

NCT02366364
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Placebo, NRX-1074 375 mg, NRX-1074 500 mg, NRX-1074 750 mg
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 22, 2016 · Synced Nov 2, 2026, 10:22 AM EST
Completed Phase 2 Interventional Results available

Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag

NCT01147809
View directory record Official record
Conditions
Thrombocytopaenia
Interventions
Eltrombopag olamine, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
33
States / cities
Sedona, Arizona • Hot Springs, Arkansas • Rancho Cucamonga, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2016 · Synced Nov 2, 2026, 10:22 AM EST
Terminated Phase 2 Interventional

Photodynamic Therapy (PDT) for Lower Urinary Tract Symptoms (PLUS)

NCT00116571
View directory record Official record
Conditions
Prostatic Hyperplasia
Interventions
Lemuteporfin for injection, Transurethral drug delivery system, Transurethral light delivery system
Drug · Device
Lead sponsor
QLT Inc.
Industry
Eligibility
21 Years and older · Male only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
8
States / cities
San Bernardino, California • Shreveport, Louisiana • Greenbelt, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2006 · Synced Nov 2, 2026, 10:22 AM EST